ClinicalTrials.gg
CompletedNCT02044276AVOIDUpdated Jun 8, 2022

A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia

A Phase 3 interventional study of lipegfilgrastim and pegfilgrastim in Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 60 sites in 3 countries. Open to participants aged 65 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-06-08.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies testing pegfilgrastim in Neutropenia — none open to participants now, none under way, none of them phase 3. pegfilgrastim · Neutropenia.

Enrollment
18th of 28
101 · median 121
Started
2014
with 1 other
Phase 3
11 of 33
none open now
Registered
25th of 33
by date

Among the 33 studies testing pegfilgrastim in Neutropenia, this one is the 18th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2014, is one of 11 in phase 3, and was the 25th registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

None of the 33 studies testing pegfilgrastim in Neutropenia is open now. The open studies under Neutropenia, anywhere →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 65 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing pegfilgrastim in Neutropenia as a file.
02

Study summary

The primary objective of the study is to demonstrate non-inferiority of lipegfilgrastim to pegfilgrastim for the duration of severe neutropenia in the first cycle of chemotherapy.

03

Conditions studied

  • Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia

Browse trials for

Keywords

  • Neutropenia
  • NHL
  • Non-Hodgkin lymphomas
  • R-CHOP-21
04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated Independent Ethics Committee (IEC)-approved written
  2. Age ≥65 years and ≤85 years
  3. Histological documentation of aggressive B cell NHL
  4. Planned to receive systemic anticancer therapy with at least 6 cycles of R-CHOP-21, according to local standards
  5. score ≤2
  6. of at least 3 months
  7. Adequate bone marrow, renal and hepatic function within 14 days before start of chemotherapy
  8. The patient is capable of understanding and complying with parameters as outlined in the protocol
  9. Women of (not surgically sterile or 2 years ) must use a medically accepted method of and must agree to continue use of this method for the duration of the treatment and for 30 days after discontinuation of study drug.
  10. The patient, if a man, is surgically sterile, or, if capable of producing offspring, is currently using an approved method of birth control and agrees to continued use of this method for the duration of the treatment (and for 90 days after taking the last dose of study

    • Other Criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  1. Participation in a clinical study within 30 days before randomization
  2. Any chemotherapy within the last 3 months before start of chemotherapy. A prephase to reduce tumor burden prior to start of R-CHOP is allowed.
  3. The patient is a pregnant or lactating woman. (Any woman becoming pregnant during the study will be withdrawn from the study.)
  4. Major surgical procedure, open , or significant traumatic injury within 28 days before start of chemotherapy.
  5. Active cardiac disease
  6. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within the 6 months before start of chemotherapy.
  7. Ongoing infection, known history of (HIV) infection, tuberculosis, or chronic or C.
  8. Patients with evidence or history of bleeding diathesis.
  9. Non-healing wound, ulcer or bone fracture.
  10. Renal failure requiring hemo- or peritoneal dialysis.
  11. Any conditions that may interfere with the patient's participation in the study or evaluation of the study results.
  12. Known to any of the study drugs, study drug classes, or in the formulation.
  13. Any illness or medical conditions that are unstable or could jeopardize the safety of the patient and his/her compliance in the study.
  14. Treatment with lithium at screening or planned during the study.

    • Other Criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    lipegfilgrastim.

    subcutaneous (SC) injection of 6 mg lipegfilgrastim

    Drug: lipegfilgrastim

  • Active comparator
    pegfilgrastim

    SC injection of 6 mg pegfilgrastim

    Drug: pegfilgrastim

Interventions

06

What researchers measure

Primary outcomes

  1. Duration of severe neutropenia (DSN) ANC <0.5 * 10^9/L

    Grade 4 neutropenia measured in days

    Time frame: 3 weeks

Secondary outcomes

  1. Incidence of febrile neutropenia (FN) (strict definition)

    Body temperature of \>38.5°C for at least one hour and ANC\<1\*10\^9/L

    Time frame: 18 weeks

  2. Incidence of FN

    A single temperature of ≥38.3°C or ≥38.0°C for at least one hour and ANC \<1 \* 10\^9/L

    Time frame: 18 weeks

  3. Incidence of very severe neutropenia

    The occurrence of at least one incidence of ANC \<0.1 \* 10\*9/L

    Time frame: 3 weeks

  4. Incidence of infections

    Incidence and severity of infections

    Time frame: 18 weeks

  5. Time to ANC recovery

    The time in days from start of chemotherapy administration until the ANC increases to ≥1.0 x 109/L, ≥1.5 x 109/L, and ≥2.0 x 109/L after the expected nadir

    Time frame: 3 weeks

  6. Summary of participants with adverse events

    Time frame: 9 Months

07

Study locations

60 sites
  • Teva Investigational Site 32284
    Aurich, 26603, Germany
  • Teva Investigational Site 32314
    Bad Soden Am Taunus, 65812, Germany
  • Teva Investigational Site 32267
    Berlin, 10117, Germany
  • Teva Investigational Site 32277
    Berlin, 10707, Germany
  • Teva Investigational Site 32292
    Bochum, 44791, Germany
  • Teva Investigational Site 32400
    Bonn, 53105, Germany
  • Teva Investigational Site 32318
    Bonn, 53113, Germany
  • Teva Investigational Site 32294
    Bottrop, 46236, Germany
  • Teva Investigational Site 32282
    Dresden, 01127, Germany
  • Teva Investigational Site 32269
    Dresden, 01307, Germany
  • Teva Investigational Site 32303
    Dresden, 01307, Germany
  • Teva Investigational Site 32308
    Frankfurt (Oder), 15236, Germany
  • Teva Investigational Site 32302
    Frankfurt-Hochst, 65929, Germany
  • Teva Investigational Site 32276
    Frechen, 50226, Germany
  • Teva Investigational Site 32293
    Freiburg, 79106, Germany
  • Teva Investigational Site 32290
    Freiburg, 79110, Germany
  • Teva Investigational Site 32322
    Fulda, 36043, Germany
  • Teva Investigational Site 32320
    Furth, 90766, Germany
  • Teva Investigational Site 32273
    Goslar, 38642, Germany
  • Teva Investigational Site 32296
    Gutersloh, 33332, Germany
  • Teva Investigational Site 32319
    Halle, 06110, Germany
  • Teva Investigational Site 32272
    Hamburg, 22081, Germany
  • Teva Investigational Site 32295
    Heilbronn, 74078, Germany
  • Teva Investigational Site 32270
    Herne, 44623, Germany
  • Teva Investigational Site 32401
    Herne, 44625, Germany
  • Teva Investigational Site 32279
    Hof, 95028, Germany
  • Teva Investigational Site 32297
    Kaiserslautern, 67655, Germany
  • Teva Investigational Site 32310
    Kassel, 34119, Germany
  • Teva Investigational Site 32280
    Kiel, 24116, Germany
  • Teva Investigational Site 32275
    Koeln, 50674, Germany
  • Teva Investigational Site 32309
    Krefeld, 47805, Germany
  • Teva Investigational Site 32287
    Lahr, 77933, Germany
  • Teva Investigational Site 32289
    Langen, 63225, Germany
  • Teva Investigational Site 32313
    Lebach, 66822, Germany
  • Teva Investigational Site 32311
    Leer, 26789, Germany
  • Teva Investigational Site 32278
    Leipzig, 04103, Germany
  • Teva Investigational Site 32281
    Mulheim, 45468, Germany
  • Teva Investigational Site 32301
    Munchen, D-81377, Germany
  • Teva Investigational Site 32274
    Oldenburg, 26121, Germany
  • Teva Investigational Site 32306
    Poessneck, 07381, Germany
  • Teva Investigational Site 32304
    Ravensburg, 88212, Germany
  • Teva Investigational Site 32291
    Rotenburg, 27356, Germany
  • Teva Investigational Site 32315
    Singen, 78224, Germany
  • Teva Investigational Site 32300
    Stade, 21680, Germany
  • Teva Investigational Site 32288
    Stolberg, 52222, Germany
  • Teva Investigational Site 32268
    Stuttgart, 70174, Germany
  • Teva Investigational Site 32321
    Stuttgart, 70376, Germany
  • Teva Investigational Site 32305
    Torgau, 04860, Germany
  • Teva Investigational Site 32266
    Villingen- Schwenningen, 78052, Germany
  • Teva Investigational Site 32317
    Villingen-Schwenningen, 78052, Germany
  • Teva Investigational Site 32286
    Weiden, 92637, Germany
  • Teva Investigational Site 30061
    Campobasso, 86100, Italy
  • Teva Investigational Site 30059
    Milano, 20162, Italy
  • Teva Investigational Site 30063
    Napoli, 80131, Italy
  • Teva Investigational Site 30062
    Torino, 10126, Italy
  • Teva Investigational Site 31074
    Barcelona, 08003, Spain
  • Teva Investigational Site 31071
    Madrid, 28006, Spain
  • Teva Investigational Site 31070
    Madrid, 28222, Spain
  • Teva Investigational Site 31073
    Valencia, 46010, Spain
  • Teva Investigational Site 31072
    Valencia, 46026, Spain
08

References and documents

Publications

  • Link H, Illerhaus G, Martens UM, Salar A, Depenbusch R, Kohler A, Engelhardt M, Mahlmann S, Zaiss M, Lammerich A, Bias P, Buchner A. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Support Care Cancer. 2021 May;29(5):2519-2527. doi: 10.1007/s00520-020-05711-7. Epub 2020 Sep 17. PubMed 32944800 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Aug 2017, 40 months.

Of 16 phase 3 interventional studies under Neutropenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2014
First posted
Jan 23, 2014
StartActual
Mar 31, 2014
Primary completionActual
Aug 29, 2017
CompletionActual
Apr 24, 2018
Last update
Jun 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02044276
Responsible party
Sponsor
First posted
Jan 23, 2014
Start date
Mar 31, 2014
Primary completion
Aug 29, 2017
Completion
Apr 24, 2018
Last update
Jun 8, 2022

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion